Abstract
The purpose of the present review was to determine which antineoplastic systemic therapy is most effective in improving clinical outcomes for patients with incurable gastroenteropancreatic neuroendocrine tumours (nets). A systematic search (2008-2016) of the literature in the medline and embase databases and the Cochrane Database of Systematic Reviews was conducted; abstracts from the American Society of Clinical Oncology, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, the European Society for Medical Oncology, the European Cancer Congress, the European Neuroendocrine Tumor Society, and the North American Neuroendocrine Tumor Society were reviewed. Draft recommendations were created, and a comprehensive review process was undertaken. Outcomes-including progression-free survival (pfs), overall survival, objective response rate, adverse events, and quality of life-were extracted from each of the studies. Eleven randomized controlled trials (rcts), sixteen nonrandomized prospective studies, and thirteen retrospective studies met the inclusion criteria. Patients with well-or moderately-differentiated pancreatic nets (pnets) should receive targeted therapy (that is, everolimus or sunitinib), and patients with non-pnets should be offered either targeted therapy (that is, everolimus) or somatostatin analogues (ssas-that is, octreotide long-acting release or lanreotide). Evidence from two phase iii trials demonstrated a significant pfs benefit for patients with pnets. For patients with non-pnets, the evidence comes from subgroup analyses of rcts, as well as from a planned interim analysis. Although the evidence has limitations, the rarity of the disease, coupled with the difficulty of conducting methodologically sound trials in the affected population, means that treatment decisions have to make use of the best available evidence. Because of insufficient evidence for both pnets and non-pnets, no evidence-based recommendation can be made for or against other types of targeted therapy, other ssas, chemotherapy, or combination therapy.
Highlights
Neuroendocrine tumours are uncommon malignancies that are located throughout the body
Neuroendocrine tumours arise from enterochromaffin cells, with the gi tract being the most common primary site, accounting for more than 60% of nets[1]
Never theless, most patients in Ontario with a net present with metastatic disease that has no option for cure and a significant effect on quality of life
Summary
Neuroendocrine tumours (nets) are uncommon malignancies that are located throughout the body. Despite their rarity, nets are, because of a longer survival period even in patients with incurable and metastatic disease, the second most prevalent gastrointestinal (gi) cancer after colon cancer. Neuroendocrine tumours arise from enterochromaffin cells, with the gi tract being the most common primary site, accounting for more than 60% of nets[1]. The incidence of nets is increasing, likely because of better detection, improved classification, and screening programs that require more widespread use of upper- and lower-bowel endoscopy, as well as improved resolution in gi imaging techniques and a heightened awareness of the disease entity. Never theless, most patients in Ontario with a net present with metastatic disease that has no option for cure and a significant effect on quality of life (qol)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
